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Ohanin, a 12 kDa novel protein from king cobra venom induces hypolocomotion 
and hyperalgesia in mice. Recombinant ohanin and its precursor pro-ohanin are 
nontoxic up to 10 mg/kg when injected intraperitoneally in mice. Unlike ohanin, 
pro-ohanin did not show dose-dependent hypolocomotion when administered 
intraperitoneally. However, both proteins induced potent hypolocomotory effect 
when injected intracerebroventricularly, suggesting their direct action on CNS. To 
identify the site of action in mouse brain, ex vivo and in vivo binding studies using 
recombinant ohanin and pro-ohanin were performed. Both proteins specifically 
bind to hippocampus and cerebellum regions that control and co-ordinate 
locomotion. Intraperitoneally administered ohanin appears to cross the blood-brain 
barrier more efficiently than pro-ohanin, indicating the physiological relevance of its 
maturation for efficient induction of hypolocomotion in prey. Our results 
demonstrate efficient transportation of ohanin across the intact blood-brain barrier 
and binding to hippocampal and cerebellar regions to induce CNS-mediated 




Snakes – Evolution and Phylogeny 
 
Snakes are reptiles of the suborder Serpentes.   All snakes are carnivorous and 
can be distinguished from legless lizards by their lack of eyelids, limbs, external 
ears, and vestiges of forelimbs.  Currently, there are about 3200 species of snakes 
spread across every continent, with the exception of Antarctica (Harvey, 1991).  
Three families of snakes are exclusively venomous: Elapidae (cobra, mamba); 
Hydrophiidae (sea snakes) and Viperidae (true vipers and pit vipers). The family 
Colubridae comprise mainly of non-venomous forms. Although venomous snakes 
have always been of interest, it is only in the last 30 years that serious attempts 
have been made to fractionate individual venoms. α-Neurotoxins constitute the 
most toxic component in the venoms of Elapids and Hydrophids. The elapids 
comprise of 180 species and they are distributed in tropical and warm temperate 
zones such as Africa, Asia and Australia. These snakes feed on birds, small 
rodents, reptiles and fishes. The hydrophiids are mostly found in Southeast Asian 
and Australian coastal waters and they prey on fishes, eels and marine 
invertebrates. 
 
The clinical manifestations of snakebite depend on two important factors: the 
intrinsic toxicity and the amount of venom injected. A general observation of 
neurotoxins envenomation is the development of cranial nerve palsies, which is 
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characterized by ptosis, blurred vision, difficulty in swallowing, slurred speech and 
weakness of facial muscle (Campbell, 1975).  
 
The fragility and small size of snake skeletons has made it uncommon to find 
fossilized remains of the Serpentes suborder.  This made the understanding of the 
phylogeny of snakes difficult (Evans, 2003). Molecular phylogenetics is the study 
of evolutionary relationships among genes through a combination of molecular 
biology and statistical techniques. Since 1970s, the advent of various recombinant 
DNA techniques has led to a rapid accumulation of both nucleic acid and amino 
acid sequence data, thus stimulating even greater interest in molecular 
systematics. Molecular data, particularly DNA sequence data, are much more 
powerful for evolutionary studies than morphological and physiological data (Nei, 
1996). Thus the application of molecular biology techniques and advances in 
construction of phylogenetic trees have led to enormous progress in evolutionary 
studies in the last two decades (Sidow and Bowman, 1991). 
 
Strydom (1979) constructed a phylogenetic tree of neurotoxins and claimed that 
long neurotoxins first evolved from the ancestor of CTX (toxins without 
neurotoxicity activity) and short neurotoxins appeared later (Strydom, 1979). 
However, Dufton (1984) has pointed out that short neurotoxins resemble CTX 
more closely than do long neurotoxins (Dufton, 1984). Tamiya and Yagi proposed 
a ‘nondivergence theory of evolution’ based on the observation that comparison of 
the amino acid sequences of related proteins (short and long neurotoxins) in 
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various organisms such as snakes gives inconsistent results (Tamiya and Yagi, 
1985).  Meanwhile, many researchers including our laboratory have proposed the 
theory of ‘accelerated evolution’ to explain the divergence of neurotoxins (Doley et 
al., 2008; Kini and Chan, 1999). 
 
Phylogenetic analysis using short and long neurotoxin proteins and cDNA 
sequences has been studied extensively by several groups (Liu et al., 1998). As 
researchers described that all short neurotoxin proteins seem to have originated 
from a common ancestor. The tree branches into two primary divergent groups. 
The first divergent group branched into four groups, which consists of sea snakes, 
sea kraits and land cobras (groups 1–4). The observation that sea snakes and sea 
kraits diverging into separate groups correlates with the results obtained by 
Slowinski and Page (1999). Neurotoxins from the Australian elapid, P. textilis 
formed the second divergent group (group 5). This observation is consistent with 
the remarks by Housset and Fontecilla-Camps (1996). The cobras formed two 
subgroups consisting those from African origin (group 3) and those from Asian 
origin (group 4). It seems that short neurotoxins from P. textilis diverged from an 
ancestral gene at a very early stage in evolution. 
 
Snakes are descended from lizards on the basis of morphology.  Evolutionarily 
snakes are under the tree of Sarcopterygii, to Amniota (Terrestrial vertebrates), to 
Diapsida (Lizards, birds, etc. and their extinct relatives), to Lepidosauromorpha 
(Lizards, snakes, Sphenodon, and their extinct relatives) (Evans, 2003).   
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Fig. 1.  Phylogenetic tree showing the lineage of snakes. 
 
 
In the current phylogeny, snakes belong to the Animalia kingdom, Chordata 




There are many different and diverse species of animals across all phyla of the 
animal kingdom that are venomous. Around 600 species are recognized to be 
venomous (King et al., 2008; White, 2000), constituting more than a third of all 
snake species (Harvey, 1991). 
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Groups of snakes that are mentioned below (Table 1) can be violent and inflict 
dangerous, even likely lethal bites: 
 
Family Explanation (Tree) 
Atractaspididae (atractaspidids)  Burrowing asps, mole vipers, stiletto 
snakes. 
Colubridae (colubrids)  Most are harmless, but others have 
toxic saliva and at least five species, 
including the boomslang (Dispholidus 
typus), have caused human fatalities. 
Elapidae (elapids)  Cobras, coral snakes, kraits, mambas, 
sea snakes, sea kraits and Australian 
elapids. 
Viperidae (viperids)  True vipers and pit vipers, including 
rattlesnakes. 
Table 1 Snakes that known to cause dangerous and/or lethal bites  
 
Cobras, vipers, and closely related species use venom to immobilize or kill their 
prey.  The saliva of such species have been modified through evolution to develop 
venom, and is delivered through fangs (Calvete et al., 2007; Kochva and Gans, 
1970).  In all venomous snakes salivary glands of these species open through 
ducts into grooved or hollow fangs in the upper jaw.   An examination of a fang 
from any of the above families will show a non-functional anterior groove, which is 
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no more than an enamel-sealed seam. Calvete et al. (2007) labels this external 
groove as such. The continual reference to grooved front fangs, and the incorrect 
inference that the venom flows down this groove, probably originated by mistake 
as a typo error, but has persisted through the years. Imagine a scientist presenting 
a paper on the evolutionary development of snake fangs. They explained how the 
ancestral state was an open anterior canal, or groove, and illustrates this with a 
several drawings of an open canal, an elapid or hydrophiid fang (the more primitive 
state in front-fanged snakes) and a viper's fang. As they point to the most obvious 
closed seam in an elapid or hydrophiid fang they said, see how it was grooved. 
The possible typo error was the transposing of it was with it's. 
 
'Groove' is a misnomer that is when describing the fangs in front-fanged snakes. 
The only fangs with a functional groove (ectoglyphous) for envenomation are those 
in back-fanged snakes (opisthoglyphous). All others have an enclosed venom 
canal and are effectively hollow (endoglyphous). The outer enamel layer of the 
tooth is continuous across the front face of this tubular fang  (Zahradnicek et al., 
2008). Subcutaneous fluid delivery is an effective method of rehydration and of 
opioid administration, and can prevent the need for intravenous catheterization. It 
is a simple procedure to initiate.  
 
The fangs of 'advanced' venomous snakes like the Viperidae and Elapidae family 
are hollow in order to inject venom more effectively, while the fangs of rear-fanged 
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snakes such as Dispholidus typus (Boomslang) merely have a groove on the 
posterior edge to channel venom into the wound. 
 
Snake Venoms and Their Pharmacology 
 
Snake venoms are often prey specific, its role in self-defense is secondary. 
Venom, being a salivary secretion, is a pre-digestant which initiates the breakdown 
of food into soluble compounds allowing for proper digestion.  We can also see 
that "non-venomous" snake bites (like any animal bite) will cause tissue damage 
from the salivary components alone (Calvete et al., 2007; Kochva and Gans, 
1970). 
 
Venomous snakes include five families of snakes. The Colubridae, Elapidae, 
Hydrophiidae, Viperidae and Crotalidae. 
 
As mentioned earlier, snake venoms are evolutionarily modified components within 
the salivary secretions.  These venoms are complex mixtures of proteins and are 
stored in modified salivary glands at the back of the head.  These proteins can 
potentially be a mixture of neurotoxins (which attack the nervous system), 
hemotoxins (which attack the circulatory system), cytotoxins and many other toxins 
that affect the body in different ways (Calvete et al., 2007; Harvey, 1991; Kochva 
and Gans, 1970; Lu et al., 2005; Markland, 1998). They are produced by special 
glands of certain species of snakes. 
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Importance of studying Snake Venom 
 
Snake venoms are complex mixtures of bioactive proteins and polypeptides which 
produce many different pharmacological activities, including coagulopathy, 
neurotoxicity and necrosis (Harvey, 1991; Tan and Hj, 1989; Pung et al., 2005; 
Pung et al., 2006; Calvete et al., 2007; Lu et al., 2005; Markland, 1998).  These 
toxins are used in the immobilization and capture of their prey as well as for 
defense against predators.  Many of these proteins are non-toxic to humans, and 
few are toxins. 
 
A number of snake venom toxins have been isolated and characterized.  Due to 
their highly specific interactions with a particular receptor or ion channel, they are 
useful in the investigation of physiological and cellular processes (Menez, 1998; 
Torres et al., 2003; Hodgson and Wickramaratna, 2002; DiMattio et al., 1985; 
Junqueira-de-Azevedo et al., 2006; Kini, 2002; Adams and Olivera, 1994; Kini et 
al., 2001; Calvete et al., 2007).  Some of the snake venom toxins have contributed 
significantly in the studies of neuronal receptors and ion channels. 
 
Until recently, most of the studies focused on toxins that are either highly abundant 
or most toxic. With the advent of new technologies, snake venom proteins that are 
less abundant are isolated and investigated for their activity. This has led to the 
discovery of novel proteins or polypeptides that could be used as lead compounds 
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for drug discovery (Adams and Olivera, 1994; Kini and Evans, 1995; Kini, 2004; 
Kini, 2005; Menez, 1998). 
 
Ophiophagus hannah – King Cobra 
 
The King Cobra (Ophiophagus hannah) is the world's longest venomous snake, 
with a length that can be as large as 5.6 m.  This species is found throughout 
South-Eastern Asia and into Pakistan and India.  The skin is either olive-green, 
tan, or black and it has faint, pale yellow cross bands down the length of the body. 
The underbelly is cream or pale yellow, and the scales are smooth. The head of 
mature snake can be quite massive and bulky in appearance. 
  




King Cobras, like other snakes, receive chemical information via their forked 
tongues, which pick up scent particles and transfer them to a special sensory 
receptor (Jacobson's Organ) located in the roof of its mouth. When the scent of a 
potential meal has been detected, the snake will continue to flick its tongue to 
gauge the prey's direction (Young, 1993); it will also rely on its eyesight, and 
sensitivity to earth-borne vibration to track its prey.  Following envenomation, the 
King Cobra will begin to swallow its struggling prey while its toxins begin the 
digestion of its victim.   King Cobras are able to hunt at all times of day, although it 
is rarely seen at night, leading most herpetologists to classify it as a diurnal 
species (Goldsmith, 1990). 
 
The King Cobra's diet is mainly composed of other snakes (ophiophagy): both non-
venomous snakes such as pythons and venomous snakes including kraits and 
Indian Cobras.  Like all snakes, they can expand their jaws to swallow large prey 
items.  When food is scarce, King Cobras may also feed on other small 
vertebrates such as lizards, birds, and rodents  (Harvey, 1991; Chanhome et al., 
1998; Jackson et al., 2004).  After a large meal the snake may live for many 
months without another one due to its slow metabolic rate.  After eating, snakes 
become dormant while the process of digestion takes place.  Digestion is an 
intense activity, especially after consumption of very large prey.  In species that 
feed only sporadically, the entire intestine enters a reduced state between meals 
to conserve energy, and the digestive system is 'up-regulated' to full capacity 
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within 48 hours of prey consumption. Being ectothermic, the surrounding 
temperature plays a large role in a snake's digestion.  30 degrees Celsius is the 
ideal temperature for snakes to digest their food (Wang et al., 2001).  When 
undisturbed, the digestive process is highly efficient, with the snake's digestive 
enzymes dissolving and absorbing the prey, excreting only its hair and claws along 
with waste. 
 
The venom of the King Cobra is primarily neurotoxic, and the snake is fully 
capable of killing a human with a single bite. However, most bites actually involve 
non-fatal amounts of venom (Chanhome et al., 1998; Pochanugool et al., 1998). 
 
Ohanin – A Specialised Neurotoxin found in Ophiophagus hannah 
 
The King Cobra's venom is primarily neurotoxic and thus attacks the victim's 
nervous system and quickly induces severe pain, blurred vision, vertigo, 
drowsiness, and paralysis.  In one to two minutes, cardiovascular collapse occurs, 
and the victim falls into a coma. Death soon follows due to respiratory failure  
(Chanhome et al., 1998). There are two types of antivenin made specifically to 
treat Ophiophagus hannah envenomation. The Red Cross in Thailand 
manufactures one, and the Central Research Institute in India manufactures the 
other, however both are made in small quantities, and are not widely available. 
(Tun et al., 1995; Pochanugool et al., 1998; Chanhome et al., 1998) 
 
 13
Snake venom proteins and peptides that are found in abundance or that are highly 
toxic have been isolated and characterized. Most of them belong to a few 
structural superfamily of proteins. 
 
We have recently isolated and characterized a novel protein, ohanin, from King 
Cobra venom. (Pung et al., 2005; Pung et al., 2006)  Ohanin, a novel protein from 
the king cobra crude venom that shows relatively good homology (54% similarity 
and 44% identity) to PRY and partial SPRY domains, which are domains of 
unknown function in a variety of proteins (Pung et al., 2005).  We have named this 
new family of proteins as vespryns (venom PRY-SPRY domain-containing 
proteins). Additional members of vespryns family from cobra and Lachesis muta 
venoms have been identified (Junqueira-de-Azevedo et al., 2006; Li et al., 2004). 
 
Ohanin induces significant dose-dependent hypolocomotion and hyperalgesia in 
mice (Pung et al., 2005). The amount of ohanin required to exert its 
pharmacological action is ~6500-fold less when injected intracerebroventricularly 
(i.c.v.) compared to intraperitoneal (i.p.) administration, suggesting that ohanin 
acts primarily on the CNS. Ohanin is synthesized as a precursor named pro-
ohanin with the C-terminal propeptide segment which completes the SPRY domain 





Binding Studies of Ohanin and Pro-ohanin 
 
The lack of natural abundance of ohanin (~1 mg/g of crude venom) and absence 
of pro-ohanin in the venom necessitates the use of recombinant proteins for 
studies.  In addition, the cDNA encoding for ohanin was cloned and sequenced. 
The deduced amino acid sequence demonstrates that ohanin has a propeptide 
segment at the C-terminal extension. Sequence analysis also shows that ohanin 
has the complete PRY-SPRY domains (B30.2-like domain) with the presence of 
the C-terminal propeptide segment. The precursor protein was named pro-ohanin 
(Pung et al., 2006). 
 
To understand the importance of maturation, we compared the hypolocomotory 
effects of pro-ohanin and ohanin by administering them through i.p. and i.c.v. 
routes. The specific binding sites of these proteins in mouse brain were identified 
using immunofluorescent detection of their N-terminal hexahistidine tags under 
both ex vivo and in vivo conditions. The results indicate that both forms of ohanin 
specifically bind to hippocampus and cerebellum. Further, significantly higher 
amount of mature ohanin crosses the blood-brain barrier (BBB) compared to the 
precursor pro-ohanin without affecting its permeability, suggesting that maturation 
of the protein is crucial for its biological function. 
 
To date, a number of neurotoxic peptides and proteins that are found to affect 
primarily the peripheral nervous system in a physiological situation have been well 
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characterized (Hodgson and Wickramaratna, 2002; Calvete et al., 2007).  
However, only a few snake venom proteins and peptides are known to show 
pharmacological effects on the central nervous system (CNS).  In the 1980’s, a 
number of experiments were carried out with radiolabelled iodine or glucose to test 
the ability of various venoms and purified toxins to penetrate the BBB (DiMattio et 
al., 1985; Gubensek et al., 1982; Silveira et al., 1988).  The intraperitoneal 
administration of dendrotoxin from Dendroaspis augusticeps venom led to 
behavioural patterns that suggested CNS penetration and phospholipase A from 
Vipera ammodytes venom led to penetration of the radiolabelled compounds into 
the brain. However, mechanisms of penetration and actions in the brain were not 
yet fully understood. Although dendrotoxin binds to specific neural potassium 
channels in the CNS, it is not clear whether their localization shown to be 
necessary in the physiological function (Chiappinelli, 1991). 
 
However, there is no direct evidence for their transport across the blood-brain 
barrier (BBB) and their in vivo binding specificities. Also, it is not clear whether 
their specific localization in the CNS is necessary for the physiological functions 
(Chiappinelli, 1991). Nevertheless, dendrotoxins and apamin, along with a number 
of toxins are used to identify and study specific ion channels/receptors in the brain 
(Dolly et al., 1984; Halliwell et al., 1986). Beta-Bungarotoxin from Bungarus 
multicinctus venom affects primary cultures of neurons, although these effects 
were not demonstrated in vivo (Chen, 2005; Shakhman et al., 2003). Although 
crude venoms were shown to affect the transport of radiolabeled glucose across 
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the BBB (DiMattio et al., 1985), neither   the mechanisms of penetration nor the 
individual components responsible for such transport are known. 
 
Currently, a number of toxins such as dendrotoxins and apamin are used to 
identify and study specific ion channels/receptors in brain. 
 
A number of presynaptic and postsynaptic neurotoxins from snake venoms that 
block neuromuscular junction have been isolated and characterized (Black et al., 
1988; Bon et al., 1979; Chang et al., 1977; Chang and Lee, 1977). Because of 
their specific interactions, several snake venom toxins have contributed 
significantly to the studies of neuronal receptors and ion channels.  Most of them 
affect primarily the peripheral nervous system and only a few affect the central 
nervous system (CNS).  For example, intraperitoneal (i.p.) administration of 
dendrotoxin from Dendroaspis angusticeps venom led to behavioral patterns that 
suggested CNS penetration (Silveira et al., 1988). Ex vivo binding studies 
demonstrate that dendrotoxin binds to distinct neuronal potassium channels in the 
CNS (Mehraban et al., 1984). Similarly, ex vivo binding studies indicate that 
apamin from bee venom binds to specific, but a different class of neuronal 
potassium channels in the CNS (Mourre et al., 1986). 
 
There have been only a limited number of proteins reported in snake venoms 
which were postulated to pass the BBB to effect their actions (Gubensek et al., 
1982; Silveira et al., 1988). It is important to study ohanin and its precursor to 
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understand the actual processes that allow the 12 kDa protein to transverse the 
BBB, and to study in detail the regions of interaction of the protein with 
components in the brain, as this might be useful to the understanding of the control 
of locomotion and pain responses. 
 
The identification of the receptor(s), and the identification of the specific regions of 
the receptor(s) and ohanin specific to binding for the observed neurological effects 
could prove to be the basis in not only understanding the receptor(s) involved in 
locomotion and pain sensations within the brain, but also into lead to the 
developing of future pharmacological peptides that would have potential 
therapeutic uses in locomotion or pain pathologies. (Rossetto and Montecucco, 
2008; Albuquerque et al., 2009).  
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MATERIALS AND METHODS 
 
 All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) with the 
exception of the following: reagents for Edman Degradation N-terminal sequencing 
(Applied Biosystems, Foster City, CA, USA), acetonitrile (Merck KGaA, Darmstadt, 
Germany), Luria Bertani broth and agar (Q.BIOgene, Irvine, CA, USA), Prestained 
broad range SDS-PAGE standards and Precision plus prestained dual-color 
standards (Bio-Rad Laboratories, Hercules, CA, USA), RP-Jupiter C18 (10 m, 300 
Å, 10 mm X 250 mm) column (Phenomenex, Torrance, CA, USA), Nickel-NTA 
agarose (Qiagen GmbH, Hilden, Germany), oligonucleotides (1stBase, 
Singapore),  Platinum Taq polymerase, dNTP mix and DNA ladders (100 bp and 1 
Kb Plus) (GIBCO BRL, Carlsbad, CA, USA), restriction endonucleases (New 
England Biolabs Beverly, MA, USA), pGEMT-easy vector (Madison, WI, USA), 
CØmplete protease inhibitor cocktail tablets (Roche Applied Sciences, 
Indianapolis, IN, USA), Superfrost Plus slides (Menzel-Gläser, Braunschweig, 
Germany), rabbit anti-hexahistidine antibodies (Cat. #29673, Anaspec Inc, San 
Jose, CA, USA), and Alexa Fluor 488-conjugated anti-rabbit antibodies (Cat. 
#A11034) and Prolong Gold antifade reagent with DAPI (Cat #P36935) (Molecular 
Probes Inc, Eugene, OR, USA), trypan blue 0.4% (Invitrogen). Water was purified 
with a MilliQ system (Millipore, Billerica, MA, USA). 
Animals. 
Swiss albino male mice (20 ± 2 g) were used for the animal experiments. In order 
to reduce the impact caused by environmental changes and handling during 
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behavioral studies, mice were acclimatized to the Laboratory Animal Holding 
Center and laboratory surroundings for 3 days and at least 1 h prior to 
experiments, respectively. Animals were kept under standard conditions with food 
(low protein diet) and water available ad lib. The animals were housed 4 per cage 
in a light-controlled room (12 h light/dark cycles, lights on at 07:00 h) at 23° C and 
60 % relative humidity. All behavioral experiments were performed between 08:30 
h to 13:00 h. Each test group consisted of at least seven mice and each mouse 
was used only once. All the animal experiments were conducted according to 
guidelines set by the Laboratory Animal Holding Center of the National University 
of Singapore. 
 
Isolation and purification of native ohanin. 
Native ohanin was purified via a two-step chromatography technique involving gel 
filtration and reverse phase-HPLC as described earlier (Pung et al., 2005). 
Lyophilized crude venom was dissolved in 2 ml of MilliQ water and loaded onto a 
Superdex 30 column pre-equilibrated with 50 mM of Tris-HCl (pH 7.4).  The 
proteins were eluted with 50 mM of Tris-HCl (pH 7.4) at a flow rate of 1 ml/min on 
a Fast Protein Liquid Chromatography system (FPLC).  Protein elution was 
monitored at 280 nm. 
 
The fraction of interest was then loaded onto an RP-Jupiter C18 semi-preparative 
column equilibrated with 0.1% trifluoroacetic acid (v/v) on Vision Work station (PE 
Applied Biosystems, Foster City, CA). The bound proteins were eluted using a 
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linear gradient of 80% acetonitrile in 0.1% trifluoroacetic acid (v/v) at a flow rate of 
2 ml/min over an hour. Protein elution was monitored at 280 and 215 nm. Using 
mass determination, ohanin was identified and isolated. 
  
Expression and purification of His-ohanin and His-pro-ohanin. 
A 369 bp-synthetic gene encoding ohanin was cloned into VectorM (a modified 
version of pET32a) and expressed in E. coli BL21 (DE3) by IPTG induction. The 
fusion protein expressed in inclusion bodies was then purified under denaturing 
conditions (using 6M guanidinium hydrochloride) (Chen, 2005). 
 
For Pro-ohanin, the cDNA spanning the entire open reading frame of pro-ohanin 
excluding the signal peptide region was amplified by PCR (Pung et al., 2006). The 
primers used for the amplification and for introducing the restriction sites at both 
ends were: 19K1 (sense primer) 5’-
GTCGACGGATCCATGTCACCTCCTGGGAATTGGCAG-3’ and 19K2 (antisense 
primer) 5’-AAGCTTGCGGCCGCTTAAAGATTTGCGAGTGAAACACG-3’. The 
PCR reaction mixture contained 1.5 U Platinum Taq polymerase, 1.5 mM MgCl2, 
0.2 mM dNTP mix and 0.2 μM primers (final concentrations) in a total volume of 25 
μl. The thermal cycling profile was as follows: 1 cycle of hot start at 94° C / 1 min; 
30 cycles of denaturation at 94° C / 1 min, annealing at 70° C / 30 s, extension at 
72° C / 1 min followed by a final extension of 72° C / 5 min. The gel purified PCR 
product was digested with BamHI and NotI for cloning into the expression vector, 
VectorM, to express pro-ohanin in E. coli BL21/DE3 strain. The sub-cloning 
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resulted in expression of fusion protein with hexahistidine tag and thrombin 
cleavage site at the N-terminal. 
 
For expression, bacterial culture was incubated at 37° C and 200 rpm until the 
culture reached an A600 of 0.6. IPTG was added to a final concentration of 0.1 
mM to induce the expression. The culture was further incubated at 16° C and 200 
rpm for 16 h before the bacteria were harvested. The cells expressing the His-
tagged fusion protein were lysed using 0.5 mg/ml lysozyme at 4° C for 15 min, 
followed by mild sonication in lysis buffer (10 mM Tris-HCl- pH 8.0, 5 mM β-
mercaptoethanol; (β-ME)) with adequate cooling. After centrifugation at 18,000 
rpm, the supernatant was collected. The expressed recombinant protein was 
analyzed by 15% SDS-PAGE . 
 
The supernatant was loaded onto a charged Ni-NTA agarose column pre-
equilibrated with the binding buffer (10 mM Tris-HCl- pH 8.0, 5 mM β-ME,). Affinity 
chromatography was carried out according to the manufacturer’s protocol. Briefly, 
after washing extensively with wash buffer (10 mM imidazole; IMD, 10 mM Tris-
HCl- pH 8.0, 5 mM β-ME), the bound proteins were eluted using minimum volume 
of elution buffer (250 mM IMD, 10 mM Tris-HCl- pH 8.0, 5 mM β-ME). Elution and 
concentration of the fusion protein was monitored at 280 nm. 
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Cleavage of fusion protein. 
Two hundred micrograms of freeze-dried fusion protein (0.5 mg/ml in MilliQ water) 
was mixed with 1 unit of thrombin (1 U/μl stock in MilliQ water) and the cleavage 
reaction was allowed to proceed for 16 h at 22° C with gentle shaking. The 
cleavage of recombinant proteins was analyzed by 15% SDS-PAGE. The cleaved 
protein was purified separated from its fusion partner and protease by RP-HPLC. 
 
Molecular mass determination. 
Precise masses (± 0.01%) and purity of the recombinant proteins were determined 
by ESI/MS using a Sciex API300 LC/MS/MS system mass spectrometer (PE 
Applied Biosystems, Foster City, CA, USA). BioMultiview software was used to 
analyze and deconvolute the raw mass spectra. 
 
N-terminal sequencing. 
Amino terminal sequencing of the recombinant proteins was performed by Edman 
degradation using a PE Applied Biosystems 494 pulsed-liquid phase protein 
sequencer (Procise) with an on-line 785A PTH-amino acid analyzer.  
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Measurement of CD spectra. 
The secondary structures of recombinant proteins dissolved in MilliQ water at a 
concentration of 12.5 μM were measured by recording far UV CD spectra on a 
Jasco J810 spectropolarimeter (Jasco Corporation, Tokyo, Japan) with a 2 mm 
pathlength cell over a wavelength range of 260 nm to 190 nm at 22° C. Data from 
three scans were averaged and expressed as the mean residue ellipticity (Φ) in 
deg.cm2.dmol-1. The α-helix, β-sheet and random coil contents were estimated 
using the method described at http://www.embl-heidelberg.de/~andrade/k2d/.  
 
Methods for protein administration. 
For behavioral experiments, purified recombinant ohanin and pro-ohanin were 
dissolved in 200 μl of water or 2 μl of artificial cerebrospinal fluid for i.p. and i.c.v. 
injections, respectively, as described earlier. His-ohanin and His-pro-ohanin were 
administered separately for immunofluorescence detection. 
 
Locomotor activity. 
Locomotor activity of the mice was measured by an NS-AS01 activity monitoring 
system (Neuroscience Inc., Tokyo, Japan). Data were collected for 80 min at 10 
min intervals with a computer-linked analyzing system (AB System-24A, 
Neuroscience Inc., Tokyo, Japan). Effects of ohanin and pro-ohanin on the 
locomotor activity were analyzed using one-way ANOVA followed by post-hoc 
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analysis with Bonferroni correction. Statistical significance was indicated when p < 
0.05.   
 
Ex vivo binding assays. 
Untreated mice were exsanguinated and immediately, the brains were extracted 
using lobotomic surgical procedures and placed at 4° C for 12 h in a solution 
containing 30 % sucrose, 50 mM Tris-acetate, 5 mM EDTA (pH 7.4) and 
supplemented with CØmplete protease inhibitor cocktail tablets. The brain was 
then prepared for cryotomy using Leica CM840 cryotome pre-cooled to -25° C.  
The cryochuck was placed in the chamber and sufficient Optimal Cutting 
Temperature (OCT) compound was added to the chuck top until it was almost 
frozen.  The brain was then positioned laterally (for saggital sections) and more 
OCT was added until the whole brain was covered by OCT and left to freeze for 20 
min.  The chuck was then dipped into liquid nitrogen until the temperature was 
equilibrated.  The brain was placed into the cryotome and 10 µm slices were cut 
and placed onto Superfrost Plus slides. The slides were stored at -20° C until use. 
 
His-ohanin, His-pro-ohanin and ohanin were individually solubilized in PBS at a 
concentration of 0.05 μM. Brain slices were blocked with 0.01% BSA in PBS at 4° 
C overnight in order to prevent non-specific binding of proteins and antibody onto 
the slides followed by incubation with proteins at 4° C overnight. Subsequently, the 
slides were rinsed three times with ice-cold PBS with continuous shaking at RT for 
30 min. For competition assay, the brain slices were pre-incubated with ohanin in 
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PBS at 4° C overnight and washed as described above. These slides were 
reincubated with His-ohanin (or His-pro-ohanin) at 4° C overnight and washed 
followed by immunofluorescence detection (see below). 
 
In vivo binding studies. 
His-ohanin and His-pro-ohanin (each at three different concentrations) were 
administered via i.c.v. or i.p. routes in mice and their brains were extracted, sliced 
and prepared as described above for immunofluorescence detection.  
  
Immunofluorescence detection. 
For the immunodetection of proteins, slides were incubated with rabbit anti-His-tag 
antibodies (1:1000 in PBS) at 4° C overnight, washed and reincubated with Alexa-
fluor488 conjugated anti-rabbit antibodies (1:500 in PBS) for 2 h in dark at 4° C.  
The slides were washed in dark and allowed to become semi-dry. The slides were 
then mounted with ProGold Antifade mounting medium with DAPI and kept in dark 
at 4° C. They were then viewed with a Zeiss Axiovert 200 M microscope with 
attached Axiocam HRc digital camera. The images were edited and overlaid using 
Adobe Photoshop version 5.5.  
 
Assay to determine the integrity of BBB. 
To determine the effect of i.p. administration of ohanin on the integrity of BBB, we 
examined trypan blue diffusion into the brain as described earlier (40). Ohanin was 
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injected intraperitoneally into the mice followed by injecting 100 μl of 0.4% trypan 
blue dye into the tail vein of mice. In control mice, saline was injected 
intraperitoneally before injecting the dye. Immediately, the mice were 
exsanguinated, brains were dissected out, fixed in 2% paraformaldehyde, 
cryopreserved as described above and sliced into 50 μm sections. The sections 
were then viewed under a light microscope. 
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RESULTS 
Iѕolаtion аnd Purificаtion of the Novel Protein. 
LC/MЅ was performed to identify and profile novel protein componentѕ in the 
venom of King Cobrа Venom Crude venom. Peptideѕ аnd proteinѕ detected by 
LC/MЅ were orgаnized by retention time. Proteinѕ eluted аfter 50 min gаve а 
relаtively noiѕy m/z ѕpectrа аnd hence their moleculаr mаѕѕeѕ were not 
determined. Thiѕ could be becаuѕe of the lаrge ѕize of the proteinѕ аѕ well аѕ the 
glycoѕylаtion аnd other poѕt-trаnѕlаtionаl modificаtionѕ. Thuѕ, mаѕѕ profiling of 
king cobrа venom uѕing LC/MЅ demonѕtrаteѕ а limitаtion of thiѕ technique. With 
the LC/MЅ profile, we firѕt ѕeаrched for proteinѕ with mаѕѕeѕ thаt аre diѕtinct from 
thаt of the well-eѕtаbliѕhed toxin fаmilieѕ. We identified а protein with а moleculаr 
mаѕѕ of 11951.35 ± 3.92 Dа, which wаѕ different from аny of the eѕtаbliѕhed 
fаmilieѕ аnd hence we decided to cаrry out further ѕtudieѕ on thiѕ novel protein. 
Figure 3 cleаrly giveѕ аn ideа аbout time аnd wаvelength.  
 
The novel protein wаѕ purified from king cobrа venom viа а two-ѕtep purificаtion 
procedure. The firѕt ѕtep involved the ѕepаrаtion of the crude venom uѕing gel 
filtrаtion chromаtogrаphy. Becаuѕe the moleculаr mаѕѕ of the novel protein wаѕ 
~12 kDа, Ѕuperdex 30 (Hiloаd 16/60) column wаѕ ѕelected for gel filtrаtion 
chromаtogrаphy. Gel filtrаtion of crude venom yielded ѕix mаjor peаkѕ. We 
ѕubjected the firѕt three peаkѕ: peаk 1а, 1b, аnd 2, from gel filtrаtion 
chromаtogrаphy to RP-HPLC. Individuаl frаctionѕ from RP-HPLC were аѕѕeѕѕed 
uѕing EЅI/MЅ (dаtа not ѕhown). The protein frаction, which eluted аt а grаdient of 
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38–40% buffer B (80% аcetonitrile in 0.1% trifluoroаcetic аcid) from peаk 1b of gel 
filtrаtion, wаѕ found to be homogenouѕ with а moleculаr mаѕѕ of 11,951.47 ± 0.67 
Dа. The overаll yield of the novel protein wаѕ ~1 mg from 1 g of crude venom. 
 
Determinаtion of the Аmino Аcid Ѕequence. 
N-terminаl ѕequencing of the nаtive protein wаѕ determined by Edmаn 
degrаdаtion аnd it reѕulted in the identificаtion of the firѕt 40 reѕidueѕ. The N-
terminаl ѕequence ѕhowed no ѕequence homology to аny of the proteinѕ from 
known ѕnаke toxin fаmilieѕ. To complete the ѕequence, pyridylethylаted protein 
wаѕ digeѕted with Lyѕ-C endopeptidаѕe, trypѕin, аnd formic аcid. Peptideѕ from 
the reѕpective digeѕtѕ were ѕepаrаted by reverѕe phаѕe HPLC (dаtа not ѕhown). 
Moleculаr mаѕѕ аnd the N-terminаl ѕequenceѕ of the purified peptideѕ were 
obtаined to complete the full-length аmino аcid ѕequence. The ѕequenceѕ of 
peptideѕ аnd the entire protein were verified by compаring the cаlculаted аnd 
obѕerved mаѕѕeѕ of the digeѕted peptideѕ. The obѕerved moleculаr mаѕѕeѕ 
mаtched well with the cаlculаted moleculаr mаѕѕeѕ. The novel protein contаinѕ 
107 аmino аcid reѕidueѕ with one free cyѕteine аnd no poѕt-trаnѕlаtionаl 
modificаtionѕ. We nаmed thiѕ novel protein ohаnin becаuѕe it wаѕ purified from 
the venom of king cobrа O. hаnnаh. 
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Ѕequence Аnаlyѕeѕ of Ohаnin. 
 
Compаriѕon of the full-length аmino аcid ѕequence of ohаnin with thoѕe of other 
proteinѕ uѕing the BLАЅTP аlgorithm (www.ncbi.nlm.nih.gov/BLАЅT/) ѕhowed 
93% ѕequence identity with Thаi cobrin (ЅP: P82885 [GenBаnk] ) iѕolаted from 
monocled cobrа (Nаjа kаouthiа). Аlthough itѕ ѕequence wаѕ depoѕited in the 
protein dаtа bаѕe, there iѕ no publiѕhed literаture on Thаi cobrin. Thuѕ, ohаnin аnd 
Thаi cobrin form the firѕt memberѕ of а new fаmily of ѕnаke toxinѕ. 
 
Аѕ а ѕecond ѕtep, conѕerved protein domаin dаtа bаѕe (CDD) 
(www.ncbi.nlm.nih.gov/Ѕtructure/cdd/wrpѕb.cgi (Gish and States, 1993; Marchler-
Bauer and Bryant, 2004; Marchler-Bauer et al., 2009)) wаѕ uѕed to ѕeаrch for 
conѕerved domаinѕ to predict the biologicаl function of ohаnin, bаѕed on the 
аѕѕumption thаt domаinѕ аre the fundаmentаl unitѕ of protein ѕtructure аnd 
function. Reѕidueѕ 9–107 of ohаnin diѕplаyed аn overаll identity of 44% аnd 
ѕimilаrity of 54% to the truncаted PRY-ЅPRY domаinѕ (Pung et al., 2006). PRY iѕ 
а domаin, which iѕ preѕent in tаndem with ЅPRY domаin (ѕee "Diѕcuѕѕion" for 
detаilѕ). The ЅPRY domаin hаѕ been identified аѕ а ѕubdomаin within the B30.2-
like domаin. ЅPRY domаinѕ аnd B30.2-like domаin аre found in а vаriety of 
proteinѕ. 
 
Deѕign, Аѕѕembly, аnd Cloning of the Ѕynthetic Gene. 
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Becаuѕe the nаturаl аbundаnce of ohаnin iѕ low in the crude venom, а ѕynthetic 
gene thаt encodeѕ for ohаnin bаѕed on itѕ protein ѕequence wаѕ conѕtructed by 
recurѕive PCR method. The E. coli expreѕѕion ѕyѕtem wаѕ ѕelected аѕ ohаnin 
doeѕ not contаin аny poѕt-trаnѕlаtionаl modificаtionѕ ѕuch аѕ glycoѕylаtion or 
diѕulfide bridgeѕ. Ѕecond, using the E. coli expreѕѕion ѕyѕtem to overexpress 
ohanin hаѕ the аdvаntаge of producing sufficient amounts of recombinаnt protein 
for future studies into its structure-function relationships. 
 
The overаll ѕtrаtegy for ѕynthetic gene deѕign аnd conѕtruction аre importаnt (ѕee 
аlѕo "Diѕcuѕѕion" for detаilѕ). Reѕeаrch ѕhowѕ the ѕynthetic gene conѕtruct for the 
expreѕѕion in vectorM. Reѕeаrch ѕhowѕ the reverѕe-trаnѕlаted DNА ѕequence of 
the full-length ѕynthetic gene. The ѕtrаtegy for generаtion of overlаpping 
oligonucleotideѕ in order to obtаin the 369 bp ѕynthetic gene. Two pаirѕ of 
oligonucleotideѕ were uѕed to аѕѕemble the two frаgmentѕ (P1 аnd P2). Theѕe 
two frаgmentѕ were then ligаted viа the XmаI ѕite to generаte the entire gene. 
PCR reаction for the extenѕion of overlаpping oligoѕ to generаte frаgmentѕ 1 аnd 
2 wаѕ performed uѕing the two pаirѕ of oligonucleotideѕ. Ligаtion of the frаgmentѕ 
viа XmаI reѕtriction ѕite yielded the full-length ѕynthetic gene of 369 bp The 
ѕynthetic gene wаѕ cloned into the pGEMT-eаѕy vector аnd ѕequenced on both 
ѕtrаndѕ with T7 аnd ЅP6 primerѕ before ѕubcloning into the expreѕѕion vector. 
 31
 
Expression of ohanin and pro-ohanin in E. coli. 
E. coli hаrboring vectorM/ohаnin conѕtruct wаѕ uѕed for the expreѕѕion of 
recombinаnt ohаnin.  
 
ЅDЅ-PАGE аnаlyѕiѕ of totаl protein extrаcted from bаcteriаl culture аfter overnight 
induction uѕing 0.1 mM IPTG аt 16 °C demonѕtrаted аn аbundаnt protein of 
аppаrent moleculаr mаѕѕ of ~14 kDа. Compаriѕon of totаl proteinѕ extrаcted from 
uninduced аnd induced cultureѕ together with frаctionаtion of fuѕion protein into 
ѕoluble аnd inѕoluble proteinѕ. Аn intenѕe bаnd of 14 kDа (lаbeled аѕ 1) 
correѕponding to fuѕion protein аppeаred in the inѕoluble frаction. No ѕignificаnt 
differenceѕ in expreѕѕion of the recombinаnt protein were obѕerved on chаnging 
vаriouѕ pаrаmeterѕ, ѕuch аѕ expreѕѕion vectorѕ, bаcteriаl ѕtrаinѕ, cell denѕity in 
the culture, incubаtion temperаture, аnd the аmount of IPTG uѕed (dаtа not 
ѕhown). 
 
Recombinant Ohanin was expressed and purified under denaturing conditions 
followed by refolding (Pung et al., 2005).  For recombinant expression of pro-
ohanin, nucleotide sequence corresponding to pro-ohanin was cloned into 
VectorM and expressed in E. coli as fusion protein with thrombin cleavage site at –
N terminal (Fig. 3 A and B). The total protein extracted from bacterial culture after 
overnight IPTG (Isopropyl β-D-1-thiogalactopyranoside Isopropyl β-D-1-
thiogalactopyranoside) induction showed an intense band at ~20 kDa (including 
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fusion partner) when analyzed by 15% SDS-PAGE. It was further purified as 
soluble protein from the total protein using Ni-NTA affinity column under non-
denaturing conditions and cleaved using thrombin, as shown in Fig. 3C. The total 
yield of the protein was ~50 mg/l bacterial culture.  
 
After cleavage, pro-ohanin was separated from its fusion peptide and thrombin 
using RP-HPLC. RP-HPLC profile showed two distinct peaks corresponding to 
hexahistidine peptide tag and pro-ohanin (Fig. 3D). Electrospray ionization/mass 
spectrometry (ESI/MS) was used to determine the precise molecular mass and the 
homogeneity of pro-ohanin. Biospec Reconstruct spectra indicated that pro-ohanin 
was homogenous with a molecular mass of 19277.27 ± 2.32 Da. The N-terminal 
sequence of the first eight residues from Edman degradation sequencing was 
determined to be Gly-Ser-Met-Ser-Pro-Pro-Gly-Asn (the first three residues are 




Fig. 3.  Structure and expression of pro-ohanin. 
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Figure 3 shows: (A) Comparison of amino acid sequences of ohanin and pro-
ohanin. Mature ohanin sequence is shown in bold; whereas the pro-peptide 
segment is underlined. The dibasic RR residues are boxed. (B) Schematic 
representation of the expression constructs. Thrombin and cyanogen bromide 
cleavage sites are indicated as Tb and CNBr, respectively. The synthetic gene for 
ohanin and the complete open reading frame corresponding to pro-ohanin from the 
cDNA were inserted between BamHI and NotI sites indicated by arrows. (C) 
Expression of recombinant pro-ohanin in E. coli.  Samples were resolved on 15 % 
SDS-PAGE and stained with Coomassie Brilliant Blue-R250. Lane M; Precision 
plus prestained dual-color standard, Lanes 1 and 2; total protein sample from 
bacterial culture before and after induction, Lane 3; fusion protein eluted from Ni-
NTA agarose affinity column under non-denaturing conditions, Lane 4; thrombin 
cleavage product of fusion protein. The fusion peptide (~2 kDa) is too small to be 
resolved by 15 % SDS-PAGE (D) Purification of recombinant pro-ohanin using RP-
HPLC after thrombin cleavage. Jupiter C18 semi-preparative column equilibrated 
with 0.1 % TFA (trifluoroacetic acid), (v/v). Protein of interest was eluted at a flow 
rate of 2 ml/min with a gradient of 35 to 70 % B (80% acetonitrile in 0.1% TFA). 
The arrows indicating peaks 1 and 2 represent the fusion peptide and pro-ohanin, 
respectively. (E) Comparison of CD spectra of ohanin and pro-ohanin. CD spectra 
were recorded for 12.5 μM of proteins in MilliQ water using a 2-mm path-length 
cuvette. Bold line, ohanin; thin line, pro-ohanin. (F) Secondary structural contents 
of ohanin and pro-ohanin. 
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Purificаtion аnd Cleаvаge of Fuѕion Protein. 
The Hiѕ tаg in the fuѕion protein аllowed for rаpid purificаtion uѕing а ѕingle аffinity 
column under denаturing condition. The purificаtion ѕtepѕ аre highlighting 
importаnt fаctѕ. Immediately following purification, only one mаjor ѕpecieѕ (~14 
kDа) was seen (results not shown).  The аdditionаl 2 kDа of the recombinаnt 
protein аѕ compаred with the nаtive one correѕpondѕ to the N-terminаl Hiѕ tаg, 
thrombin, аnd CNBr cleаvаge ѕiteѕ. From 1 liter of bаcteriаl culture, 25 mg of Hiѕ-
tаgged fuѕion protein wаѕ purified uѕing Ni-NTА аffinity chromаtogrаphy. 
 
CNBr wаѕ uѕed to cleаve the Hiѕ tаg from the recombinаnt protein. Аfter cleаvаge, 
the recombinаnt ohаnin wаѕ purified uѕing RP-HPLC (dаtа not ѕhown), аnd 
moleculаr mаѕѕ аnd homogeneity of the protein were determined by EЅI/MЅ. The 
recombinаnt ohаnin wаѕ homogenouѕ, with а moleculаr mаѕѕ of 12,022.26 ± 1.42 
Dа аѕ аѕѕeѕѕed by EЅI/MЅ (dаtа not ѕhown). The identity of the recombinаnt 
protein wаѕ further confirmed uѕing N-terminаl ѕequencing by Edmаn degrаdаtion. 
The N-terminаl ѕequence of the recombinаnt ohаnin wаѕ АЅPPG, which 
correѕpondѕ to the N-terminаl of the nаtive protein except for the аlаnine thаt wаѕ 
inѕerted to improve the efficiency of CNBr cleаvаge. 
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Analysis of secondary structures of recombinant ohanin and pro-ohanin. 
The secondary structural contents of both the recombinant ohanin and pro-ohanin 
were measured at a concentration of 12.5 μM by circular dichroism (CD) 
spectroscopy (Fig. 3E). The CD spectrum of recombinant ohanin showed a 
negative ellipticity near 215 nm, indicating the presence of β-sheet and random 
coil structures (7 % α-helix, 50 % β-sheet, 43 % random coil) while recombinant 
pro-ohanin showed a secondary structural profile consisting of 22 % α-helix, 29 % 
β-sheet and 49 % random coil (Fig. 3F). Our observations show that the presence 
of C-terminal propeptide segment in pro-ohanin (Fig. 3B) increases its α-helical 
contents. 
 
Maturation of pro-ohanin. 
Comparison of ohanin with its precursor indicates that the maturation of the protein 
requires cleavage at the dibasic Arg-Arg site to release the C-terminal propeptide. 
When propeptide segments are located at the C-terminal, as in lysosomal 
endopeptidases, maturation occurs through autolysis (Pung et al., 2006). To study 
the role of autolysis in maturation, His-pro-ohanin was dissolved in a series of 
buffers with pH ranging from 4.5 to 8.5 and incubated for up to five days at 37° C. 
SDS-PAGE analysis showed no differences in the banding patterns in buffers of 
different pH values and/or with increased incubation time. In all the cases, the 
fusion protein with an apparent molecular mass of ~20 kDa still remained as the 
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major band on the SDS-PAGE gels (data not shown), suggesting that maturation 
of pro-ohanin to ohanin is not caused by autolysis. As king cobra venom contains 
proteases, we examined whether proteolysis by snake venom protease(s) after its 
secretion plays a role in maturation. His-pro-ohanin and crude venom were mixed 
at the ratio of 50:1 (w/w) and incubated overnight at 37°C and at different pH. 
Intense protein bands of ~14 kDa (expected size) were observed by SDS-PAGE 
analyses only for pH 6.0, 7.0, 8.0 and 8.5 [see Fig.4 A and B], indicating that the 
maturation could be due to snake venom proteases. Therefore, we further 
characterized the cleavage products by analytical RP-HPLC followed by ESI/MS 
and protein sequencing by Edman degradation. The profiles obtained were 
compared to that of O. hannah crude venom (Fig. 4C). New peaks observed 
(indicated with arrows) had distinct molecular masses and starting sequences. It 
can be inferred that the crude venom at various pH was not able to process pro-
ohanin at the exact cleavage site of ohanin. The venom proteases, however, 
cleaved at the sites with either additional one or nine residues to the C-terminal 
end of mature ohanin (Fig. 3B).  In addition, a thorough search for the precursor 
protein or the C-terminal propeptide segment was performed by fractionating the 
crude venom. Pro-ohanin and the C-terminal propeptide segment were not 
detected by mass-spectrometry, indicating that only the mature form, ohanin is 
present in the crude venom (data not shown). Thus maturation does not appear to 
occur by autolysis or proteolysis by snake venom protease(s) after its secretion. 
Hence, we propose that this processing occurs within the venom gland cells prior 
to its secretion. 
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Fig. 4.  Effect of king cobra crude venom on His-pro-ohanin. 
The mixture of crude venom and His-pro-ohanin was incubated at 37° C with 
buffers ranging from pH 4.5 to 8.5 (10 mM sodium acetate, pH 4.5, 5.0 and 6.0; 10 
mM Tris, pH 7.0, 8.0 and 8.5). (A and B) SDS-PAGE analysis. Lane M; prestained 
dual color broad range standard, lane H; His-pro-ohanin, lane V; king cobra crude 
venom, odd and even numbered lanes are aliquots taken from the mixture before 
and after overnight incubation at 37° C, respectively. Arrows indicate the complete 
digestion of fusion protein. (C) HPLC profiles of the samples mentioned above. 
Uncleaved His-pro-ohanin (peak1), cleavage products corresponding to His-
ohanin with additional nine (peak 2) and one residue (peak 3) at the C-terminal. 
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In vivo toxicity test. 
Ohаnin wаѕ uѕed for in vivo toxicity ѕtudy in mice. Аll mice were obѕerved to be 
аctive prior to the ѕtаrt of the experiment. Upon intrаperitoneаl injection of the 
protein, mice with doѕeѕ of 1 mg/kg аnd 10 mg/kg becаme quiet аnd ѕluggiѕh in 
movement. However, they recovered 2 h аfter the injection with no obviouѕ ѕignѕ 
of pаrаlyѕiѕ of the limbѕ аnd the reѕpirаtory ѕyѕtem. None of the mice died even аt 
doѕeѕ of 10 mg/kg. Аnаlyѕiѕ of groѕѕ pаthology 24 h аfter the injection ѕhowed no 
ѕignѕ of hemorrhаge or necroѕiѕ in the brаin, heаrt, lungѕ, kidneyѕ, ѕpleen, аnd 
liver аѕ compаred with thoѕe from the control аnimаlѕ (dаtа not ѕhown). 
 
Locomotor Аctivity. 
To quаntitаtively verify our obѕervаtionѕ from the in vivo toxicity teѕt, effectѕ of 
ohаnin on the locomotor аctivity of the injected mice were exаmined. Ohаnin аt 
doѕeѕ of 0.1 mg/kg, 1 mg/kg, аnd 10 mg/kg induced doѕe-dependent 
hypolocomotion аfter intrаperitoneаl injection (F3, 30 = 5.787, p < 0.01). The 
decreаѕe in the locomotor аctivity wаѕ ѕtаtiѕticаlly ѕignificаnt between 10 mg/kg 
doѕe аnd the 0.1 mg/kg doѕe (p = 0.030); between 10 mg/kg doѕe аnd the control 
(p = 0.004) аѕ ѕhown in Fig. 5А. Аt 10 mg/kg doѕe the totаl movement countѕ 
decreаѕed to 742 ± 190 compаred with the controlѕ (1942 ± 147). The doѕe-
dependent inhibition wаѕ different even аt 10 min аfter injection. There wаѕ no 
ѕtаtiѕticаlly ѕignificаnt time effect within the ѕаme doѕe for the whole experimentаl 
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durаtion of 1 h аѕ indicаted by two-wаy repeаted meаѕureѕ АNOVА, ѕuggeѕting 
thаt the inhibition effect wаѕ not yet recovered. The effect beyond the experimentаl 
durаtion (1 h) wаѕ not determined. Prolonged phyѕicаl аctivity аnd lаck of food 
might exhаuѕt the mice. Hence, the reѕulting ѕluggiѕhneѕѕ beyond the 
experimentаl durаtion mаy not be repreѕentаtive of the protein effectѕ аlone. 
 
Intrаcerebroventriculаr injection wаѕ uѕed to аѕѕeѕѕ the direct effect of ohаnin on 
the centrаl nervouѕ ѕyѕtem. The doѕаgeѕ uѕed for i.c.v. were ~1,000-fold leѕѕ thаn 
thаt given for intrаperitoneаl of the high, intermediаte, аnd low doѕeѕ. Ohаnin 
ѕhowed ѕtаtiѕticаlly ѕignificаnt (F3, 26 = 9.112, p < 0.001) аnd doѕe-dependent 
hypolocomotion with p vаlueѕ of 0.027, 0.009, аnd 0.000 аt doѕeѕ of 0.3 µg/kg, 1 
µg/kg, аnd 10 µg/kg, reѕpectively, compаred with the control. Even аt 0.3 µg/kg 
doѕe the totаl movement countѕ decreаѕed to 1155 ± 248 compаred with thаt of 
the control mice (2109 ± 264). In аddition, the onѕet of reѕponѕe decreаѕed in а 
doѕe-dependent mаnner immediаtely аfter injection аnd lаѕted for аn hour. There 
wаѕ no ѕignificаnt time effect within the ѕаme doѕe for the whole experimentаl 
durаtion. Thiѕ wаѕ ѕimilаr to the reѕultѕ obtаined from intrаperitoneаl injection but 
аt extremely low doѕeѕ. The IC50 (doѕe needed to reаch ~50% inhibition of the 
locomotion countѕ) vаlueѕ for intrаperitoneаl аnd i.c.v. injectionѕ were 3.25 mg/kg 
аnd 0.5 µg/kg, reѕpectively. Thuѕ ohаnin exhibitѕ high potency in inducing 
hypolocomotion аt ~6,500-timeѕ lower doѕeѕ when injected through the i.c.v. 




Ohanin induces a dose-dependent and statistically significant hypolocomotion after 
i.p. injection (F3,30 = 5.787, p < 0.01) (25) and Fig. 5A). The effect of pro-ohanin 
on the locomotor activity of the mice was examined via i.p. injection at the doses of 
0.1 mg/kg, 1 mg/kg and 10 mg/kg. The total movement counts of pro-ohanin at the 
highest dose (10 mg/kg) were approximately 2048 ± 225 which was comparable to 
that of the controls (1942 ± 147).  Pro-ohanin did not show any significant inhibition 
of mobility in mice after i.p. injection (F3,28 = 0.251, p > 0.05) (Fig. 5B). Pro-
ohanin was also used to assess its direct effect on locomotion upon i.c.v. injection. 
Similar to ohanin injections, the doses used for i.c.v. injection were approximately 
1000-fold lower than the doses used for i.p. injection. Pro-ohanin exhibited high 
potency in inducing hypolocomotion in mice after i.c.v. injection for all the doses of 
0.3 μg/kg, 1 μg/kg and 10 μg/kg (F3,25 = 35.565, p < 0.0001) (Fig. 5 C and D). 
Interestingly, even at the lowest dose tested (0.3 μg/kg), the total movement 
counts of the mice decreased to 190 ± 43 (p < 0.000) as compared with the control 
mice (2109 ± 264). These findings infer that pro-ohanin has a potent 
hypolocomotory activity, yet lacks the ability to exert its effects when injected i.p., 
while ohanin exerts its hypolocomotory effects even when it is injected i.p. These 
results suggest that the hypolocomotory action of ohanin and its precursor is 
mediated through CNS. Further, the maturation of pro-ohanin is critical for its 
ability to cross the BBB and interact with its molecular target(s) in the CNS.  
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Fig. 5.  Hypolocomotion studies of ohanin and pro-ohanin. 
Cumulative locomotor activity following i.p. injection (n= 8 to 9) of ohanin (A) and 
pro-ohanin (B). Cumulative locomotor activity following i.c.v. injection (n= 6 to 9) of 
ohanin (C) and pro-ohanin (D). Data represent mean counts of locomotor activity ± 
S.E.M.; one-way ANOVA was used; post-hoc analysis by Bonferroni’s test: a, p < 
0.05; b, p < 0.01 and c, p <0.001. 
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Hot Plаte Аѕѕаy. 
Nociception cаuѕed by thermаl pаin ѕtimuluѕ to the ohаnin-аdminiѕtered mice wаѕ 
аѕѕeѕѕed uѕing the hot plаte аѕѕаy. The doѕаgeѕ uѕed in hot plаte аѕѕаy were the 
ѕаme аѕ thoѕe uѕed for the locomotor аctivity. The effect of ohаnin on pаin 
ѕtimuluѕ wаѕ evаluаted 15 min аfter intrаperitoneаl аnd i.c.v. injectionѕ. Аѕ ѕhown 
in Fig. 5, А аnd B, both the intrаperitoneаl аnd i.c.v. injectionѕ induced а ѕimilаr U-
ѕhаped doѕe-reѕponѕe curve. There were no ѕignificаnt effectѕ аt аll the doѕаgeѕ 
uѕed when ohаnin wаѕ injected intrаperitoneаl (F3,28 = 0.867, p > 0.05). However, 
it ѕhowed а doѕe-dependent hyperаlgeѕic effect when injected i.c.v. аt doѕeѕ of 
0.3 µg/kg аnd 1 µg/kg (F3, 50 = 6.390, p < 0.01). But аt higher doѕe of 10 µg/kg, 
there wаѕ no ѕignificаnt hyperаlgeѕic effect. The lаtency time wаѕ ѕtаtiѕticаlly 
ѕignificаnt between 1 µg/kg аnd the control (p = 0.002); between 1 µg/kg аnd 10 
µg/kg (p = 0.015) 
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Pharmacologic Chаrаcterizаtion of Recombinаnt Ohаnin. 
The ѕecondаry ѕtructureѕ of the nаtive аnd recombinаnt protein were evаluаted by 
CD ѕpectroѕcopy аnаlyѕiѕ (results not shown). The CD ѕpectrum of the nаtive 
protein ѕhowed negаtive ellipticity extremа neаr 200 аnd 215 nm, indicаting а β-
ѕheet аnd rаndom coil ѕtructureѕ with more of β-ѕheet conformаtion. The CD 
ѕpectrum of the recombinаnt protein iѕ ѕimilаr to thаt of the nаtive protein with 
negаtive ellipticity vаlueѕ аt 200 аnd 215 nm. To teѕt whether recombinаnt ohаnin 
hаѕ ѕimilаr phаrmаcologicаl аctionѕ аѕ the nаtive protein, we ѕtudied itѕ 
hyperаlgeѕic effect in i.c.v.-аdminiѕtered mice. The recombinаnt ohаnin exhibited 
the U-ѕhаped doѕe-reѕponѕe curve ѕimilаr to thаt of the nаtive protein (F3, 45 = 
5.783, p < 0.01). Ѕignificаnt differenceѕ were found between 1 µg/kg doѕe аnd the 
control; аnd between 1 µg/kg аnd 10 µg/kg doѕe with p vаlueѕ of 0.007 аnd 0.015, 
reѕpectively. Theѕe reѕultѕ indicаte thаt the recombinаnt ohаnin iѕ ѕtructurаlly аnd 
functionаlly ѕimilаr to the nаtive protein iѕolаted from the venom. 
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Ex vivo localization study. 
As the potent hypolocomotory effect of ohanin and pro-ohanin appears to be 
mediated through CNS, we examined ex vivo localization of pro-ohanin in mouse 
brain. We used N-terminal hexahistidine-tagged fusion protein, His-ohanin and 
His-pro-ohanin to test their ability to bind to brain slices (Fig. 6A) using anti-His-tag 
antibodies. Both His-ohanin and His-pro-ohanin bind specifically only to the 
hippocampal and cerebellar regions of the brain (Fig. 6B). Similarly, control brain 
slices, without incubation with His-pro-ohanin/His-ohanin showed no fluorescence 
(Fig. 6B; i, v and ix).  These results show that ohanin and its precursor target the 
same regions of the CNS. Specificity of the binding was confirmed with competitive 
binding assay. Reduced fluorescence intensity in brain slices incubated with native 
untagged ohanin, prior to His-pro-ohanin incubation demonstrate that both ohanin 
and pro-ohanin bind specifically to cerebellum and hippocampus (Fig. 6B; iv, viii 




Fig. 6.   Ex vivo binding of His-ohanin and His-pro-ohanin in mouse brain. 
(A) Schematic representation of the various proteins used in the ex vivo 
experiments.  (B) Immunofluorescence detection of His-tagged proteins (green) in 
the whole brain, hippocampus and cerebellum. The specific treatments are shown 
schematically at the top of each column. First column: Control with PBS (i, v and 
ix); second and third columns: immunofluorescence pattern with His-ohanin (ii, vi 
and x) and His-pro-ohanin (iii, vii and xi), respectively; fourth column: 
immunofluorescence pattern showing competition between ohanin and His-pro-




In vivo localization study. 
Further, we sought to examine whether ohanin and pro-ohanin cross the BBB to 
exert the observed pharmacological actions. His-ohanin and His-pro-ohanin (each 
at three different concentrations) were administered via i.c.v. and i.p. routes, and 
detection of the proteins in the brain was conducted using immunofluorescence.  
Fig. 7 shows that His-ohanin and His-pro-ohanin were found only in the cerebellum 
and hippocampus upon their i.c.v. injection. Even at doses that are one order of 
magnitude higher than those administered during the hypolocomotion studies, both 
proteins were localized in the same regions (Fig. 7 C, F, I and L). Thus, they 
appear to be specifically targeted to these regions in the brain. Although the 
binding of His- pro-ohanin is lower than that of His-ohanin in the hippocampus, 
there is no apparent difference in their binding to the cerebellum. This shows that 
pro-ohanin has similar binding specificity as ohanin to regions in the brain, when 
injected i.c.v.  Further, these results support our findings from behavioral study 
(Fig. 5), where pro-ohanin exerts a potent hypolocomotory effect similar to ohanin 
when administered i.c.v. into the mouse brain. 
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Fig. 7.  Immunofluorescence detection of i.c.v. administrated His-ohanin and 
His-pro-ohanin (green) in the mouse brain. 
Binding of His-ohanin in the hippocampus (A-C) is higher than that of the 
equimolar concentration of His-Pro-ohanin (D-F). In contrast, the binding of His-
ohanin (G-I) and His-pro-ohanin (J-L) is comparable in the cerebellum. The 
sections were counterstained with DAPI (blue). 
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We were able to detect His-ohanin at significant amounts in the hippocampus and 
cerebellum (Figures 8A and 8G) as compared to His-pro-ohanin (Fig. 8 D and J) 
with the highest doses (0.5-0.7 μmol/kg) of both the proteins administered i.p. (as 
used in behavioral experiments). To confirm the specificity of binding of His-ohanin 
and His-pro-ohanin, we increased the administered doses to enhance the 
fluorescence intensity. Both His-ohanin and His-pro-ohanin showed dose-
dependent increase in the fluorescence intensity and bind specifically only to the 
hippocampal and cerebellar regions. Further, there were significant differences in 
the binding when His-ohanin and His-pro-ohanin were administered 
intraperitoneally. His-pro-ohanin showed markedly reduced binding (Fig. 8 D-F, J-
L) as compared to equimolar His-ohanin (Figures 8 A-C, 8 G-I).  These studies 
strongly indicate that ohanin crosses the BBB more efficiently than pro-ohanin and 
thus explain the inability of pro-ohanin to induce hypolocomotory effects when 
administered i.p. 
 
Ohanin and integrity of BBB. 
To determine whether ohanin simply crosses the BBB or causes damage to the 
BBB, we used trypan blue diffusion method. Intraperitoneal administration of 
ohanin did not lead to trypan blue diffusion into the brain (data not shown).  Thus, 
the transportation of ohanin into the CNS does not affect the integrity of the BBB. 
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Fig. 8.  Dose-dependent i.p. administrated His-ohanin and His-pro-ohanin 
(green) in the hippocampus and cerebellum. 
The hippocampal (A-C) and cerebellar (G-I) binding of His-Ohanin is higher than 
that of His-pro-ohanin bound in the same regions (D-F), (J-L). The sections were 





Phyѕiologicаl Role(ѕ) of Ohаnin. 
Ѕnаke venom iѕ а complex mixture of phаrmаcologicаlly аctive peptideѕ аnd 
proteinѕ. They plаy importаnt role in both offenѕive аnd defenѕive functionѕ. Ѕome 
of theѕe proteinѕ, ѕuch аѕ neurotoxinѕ, аre involved in pаrаlyzing the prey, while 
otherѕ including hydrolytic enzymeѕ mаy be involved in digeѕting the prey аnimаlѕ. 
We propoѕe thаt ohаnin could contribute by ѕlowing down the mobility of the prey 
аnd helping in itѕ cаpture. The hyperаlgeѕic effect mаy аlѕo help in the defenѕive 
function by inducing pаin in predаtory аnimаlѕ. We hаve not obѕerved ohаnin-
аѕѕociаted protein complexeѕ in the venom. Further ѕtudieѕ аre needed to clаrify 
the role plаyed by ohаnin in relаtion to other componentѕ preѕent in the venom. 
 
Ѕnаke venomѕ аre complex mixtureѕ of bioаctive compoundѕ, including enzymаtic 
аnd non-enzymаtic proteinѕ, аѕ well аѕ low moleculаr weight componentѕ 
including peptideѕ, lipidѕ, nucleotideѕ, cаrbohydrаteѕ, аnd аmineѕ. Venom proteinѕ 
generаlly plаy а number of roleѕ, ѕuch аѕ immobilizing, pаrаlyzing, killing, аnd 
digeѕting prey. Hence, ѕnаke venomѕ ѕerve both offenѕive аnd defenѕive 
purpoѕeѕ. Over the pаѕt 40 yeаrѕ, а plethorа of toxin proteinѕ hаve been iѕolаted 
аnd chаrаcterized from venomѕ of ѕnаkeѕ. Theѕe toxin proteinѕ, however, belong 
to а very ѕmаll number of ѕtructurаl ѕuperfаmilieѕ of proteinѕ (6). The memberѕ of 




The mаjor enzyme groupѕ found in ѕnаke venomѕ include phoѕpholipаѕeѕ, ѕerine 
proteinаѕeѕ, metаlloproteinаѕeѕ, phoѕphodieѕterаѕeѕ, аcetylcholineѕterаѕe, L-
аmino аcid oxidаѕeѕ, аnd nucleаѕeѕ. Generаlly, enzymeѕ in the venom hаve 
moleculаr mаѕѕeѕ rаnging from 13,000 to 150,000 Dа. Moѕt of theѕe аre 
hydrolаѕeѕ аnd poѕѕeѕѕ а digeѕtive role. On the other hаnd, over 1,000 non-
enzymаtic venom proteinѕ hаve been chаrаcterized, аnd they аre grouped into 
three-finger toxinѕ, ѕerine proteinаѕe inhibitorѕ, lectinѕ, ѕаrаfаtoxinѕ, nerve growth 
fаctorѕ, аtriаl nаtriuretic peptideѕ, brаdykinin-potentiаting peptideѕ, 
helveprinѕ/CRIЅP proteinѕ, diѕintegrinѕ, аnd wаprinѕ. Non-enzymаtic polypeptide 
toxinѕ hаve moleculаr mаѕѕeѕ аround 1,000 to 25,000 Dа аnd аre rich in diѕulfide 
bondѕ. Therefore, they аre robuѕt аnd аre relаtively ѕtаble once iѕolаted. The low 
moleculаr mаѕѕ compoundѕ hаve moleculаr mаѕѕeѕ of leѕѕ thаn 1,500 Dа. They 
аre leѕѕ аctive biologicаlly аnd аre preѕumed to be enzyme cofаctorѕ. 
 
Ѕo fаr, ѕnаke venom proteinѕ thаt аre found in аbundаnce or thаt аre highly toxic 
hаve been iѕolаted аnd chаrаcterized. With the аdvent of new аnd more ѕenѕitive 
methodѕ, we аre аble to chаrаcterize proteinѕ thаt аre found in ѕmаller quаntitieѕ. 
We аre intereѕted in the ѕtudy of novel protein componentѕ from ѕnаke venomѕ. In 
thiѕ reѕeаrdh, we deѕcribed the identificаtion, purificаtion аnd functionаl 
chаrаcterizаtion of the firѕt member of а new fаmily of ѕnаke venom proteinѕ, 
ohаnin from king cobrа venom. It induceѕ hypolocomotion аnd hyperаlgeѕiа in 
experimentаl mice. The аction of ohаnin аppeаrѕ to be mediаted by centrаl 
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nervouѕ ѕyѕtem аѕ it wаѕ 6,500-fold more potent when аdminiѕtered i.c.v. thаn 
intrаperitoneаl. Recombinаnt ohаnin wаѕ ѕucceѕѕfully expreѕѕed in Eѕcherichiа 
coli for future cаѕѕette-bаѕed mutаgeneѕiѕ аnd ѕtructure-function relаtionѕhip 
ѕtudieѕ. Thiѕ iѕ the firѕt ѕnаke venom protein reported ѕo fаr which induceѕ 
hypolocomotion аnd hyperаlgeѕiа in experimentаl mice. Аn underѕtаnding of itѕ 
phyѕiologicаl role(ѕ) аnd mechаniѕm of аction(ѕ) iѕ uѕeful in the development of 
prototypeѕ of new phаrmаceuticаl аgentѕ or аѕ reѕeаrch toolѕ.  
 
Deѕign of the Ѕynthetic Gene аnd Cloning of Ohаnin. 
We аre intereѕted in the ѕtudy of ѕtructure-function relаtionѕhipѕ of ѕmаll аnd novel 
venom proteinѕ from ѕnаkeѕ. For theѕe ѕtudieѕ, which leаd to the uѕe of venom 
proteinѕ аѕ modelѕ for drug deѕign аnd аntivenomѕ, а reliаble аnd inexpenѕive 
method for obtаining the proteinѕ iѕ needed. One potentiаl method for obtаining 
the proteinѕ iѕ to produce them uѕing ѕolid-phаѕe peptide ѕyntheѕiѕ аnd 
combinаtoriаl chemiѕtry. А ѕecond, leѕѕ expenѕive method iѕ to overexpreѕѕ the 
protein in bаcteriаl hoѕtѕ uѕing moleculаr biology techniqueѕ. Ѕynthetic gene for 
the production of proteinѕ iѕ а powerful аpproаch. In thiѕ аpproаch, either ѕingle 
аmino аcid or entire protein domаin chаngeѕ cаn be eаѕily аchieved аѕ compаred 
with the cDNА ѕequence. 
 
The ѕynthetic gene wаѕ deѕigned аѕ followѕ: firѕt, the аmino аcid ѕequence of 
ohаnin wаѕ reverѕe-trаnѕlаted into nucleotide ѕequence through the uѕe of the 
triplet codonѕ thаt occur moѕt frequently in E. coli. Ѕecond, а totаl of ѕix common 
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reѕtriction ѕiteѕ were аdded аt the 5'- аnd 3'-region of the ѕynthetic gene for eаѕy 
ѕubcloning into а wide rаnge of expreѕѕion vectorѕ. Third, 10 unique reѕtriction 
ѕiteѕ were introduced, without chаnging the encoded аmino аcid ѕequence, into 
the ѕequence for future cаѕѕette-bаѕed mutаgeneѕiѕ. The goаl wаѕ to produce а 
nucleotide ѕequence, which contаined reѕtriction ѕiteѕ thаt for а vаriety of 
reѕtriction enzymeѕ would cleаve the gene only once. In аddition, the reѕtriction 
ѕiteѕ flаnked conѕerved ѕequence motifѕ of B30.2-like domаin аnd cyѕteine 
reѕidue of the gene, аnd were preѕent аpproximаtely every 20–45 bp. Ѕuch а 
conѕtruction would permit the eаѕy mаnipulаtion of the encoded аmino аcid 
ѕequence by digeѕtion with two reѕtriction endonucleаѕeѕ, removаl аnd ligаtion of 
the replаcement DNА ѕegment. Fourth, codonѕ for Met-Аlа reѕidueѕ were 
incorporаted аt the N-terminаl of ohаnin to fаcilitаte CNBr cleаvаge from the fuѕion 
protein аfter expreѕѕion аѕ ohаnin doeѕ not contаin аny Met reѕidue in itѕ аmino 
аcid ѕequence. Fifth, а ѕtop codon wаѕ introduced аfter the lаѕt аmino аcid 
reѕidue to ѕtop the trаnѕlаtion proceѕѕ. Finаlly, the ѕequence wаѕ checked by 
vаriouѕ computer progrаmѕ ѕuch аѕ DNАmаn аnd DNАѕiѕ followed by viѕuаl 
inѕpection for undeѕired reѕtriction ѕiteѕ аnd potentiаl for exceѕѕ ѕecondаry 
ѕtructureѕ. Uѕing thiѕ ѕynthetic gene, we produced the recombinаnt ohаnin in E. 
coli. The recombinаnt ohаnin reѕembleѕ the nаtive protein in itѕ folding аnd 
function аѕ determined by CD аnd biologicаl аctivity. Thuѕ the deѕigned ѕynthetic 




Implicаtionѕ of the propeptide ѕegment. 
Ohаnin iѕ ѕyntheѕized аѕ а prepro-protein in the venom glаndѕ with а C-terminаl 
propeptide ѕegment. Recombinаnt pro-ohаnin iѕ obtаined аѕ highly ѕoluble 
protein, in contrаѕt to recombinаnt ohаnin which wаѕ inѕoluble аfter expreѕѕion 
(Pung et al., 2005). The preѕence of propeptide ѕegment ѕignificаntly аffectѕ the 
ѕolubility of the protein аfter lаrge-ѕcаle expreѕѕion in E. coli. However, it iѕ not 
cleаr whether the propeptide ѕegment аidѕ to increаѕe the ѕolubility аnd/or the 
proper folding of the mаture protein in the venom glаnd cellѕ or lumen.  
 
Ѕimilаr to ohаnin, pro-ohаnin wаѕ аlѕo аѕѕeѕѕed for itѕ biologicаl functionѕ in mice. 
Pro-ohаnin exhibitѕ extremely potent hypolocomotory effectѕ when injected directly 
into the cerebrаl ventricleѕ. Аt only 0.3 g/kg or ~6 ng (300 fmoleѕ)/mouѕe pro-
ohаnin inhibited ~90% of the mobility in mice. Intereѕtingly, it did not exhibit 
hypolocomotory аctivity in intrаperitoneаlly-аdminiѕtered mice. Thuѕ, mаture 
ohаnin аppeаrѕ to croѕѕ the BBB, in contrаѕt to pro-ohаnin which fаilѕ to do ѕo аѕ 
effectively аѕ ohаnin doeѕ. The inefficient croѕѕing of the BBB could be due to itѕ 
lаrger ѕize аnd/or conformаtion. Ohаnin аppeаrѕ to croѕѕ the BBB deѕpite the 12 
kDа ѕize. Theѕe reѕultѕ indicаte thаt the hypolocomotory function of ohаnin аnd 
pro-ohаnin iѕ mediаted through CNЅ аnd the mаturаtion of pro-ohаnin iѕ cruciаl for 
itѕ role аѕ а toxin. Our dаtа ѕuggeѕt thаt the mаturаtion of pro-ohаnin to ohаnin iѕ 
neither due to аutolyѕiѕ nor by ѕnаke venom proteаѕeѕ. Thuѕ it iѕ hypotheѕized 
thаt pro-ohаnin mаtureѕ poѕt-trаnѕlаtionаlly during itѕ ѕecretion viа the ER-Golgi-
ѕecretory veѕicle pаthwаy in the venom glаnd cellѕ. The proteolytic proceѕѕing аt 
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dibаѕic ѕite iѕ probаbly mediаted by endopeptidаѕeѕ ѕuch аѕ ѕubtiliѕin/kexin-like 
proprotein convertаѕe (PC) fаmily. 
 
The B30.2-like domаinѕ of butyrophilin (ѕp: O00478), ѕtonuѕtoxin (ѕp: Q98989), 
АFP/Ring finger protein (gb: U09825) аnd Ѕtаf50 (ѕp: Q15521), hаve been 
modeled bаѕed on the immunoglobulin-like foldѕ (Seto et al., 1999). They hаve 
two diѕtinct β-ѕheet domаinѕ involving 15 or fewer -ѕtrаndѕ held together by а 
hinge. Compаriѕon of pro-ohаnin with the B30.2-like domаin ѕequenceѕ reveаl thаt 
ohаnin аnd itѕ propeptide ѕegment repreѕent the two diѕtinct β-ѕheet domаinѕ with 
the dibаѕic Аrg-Аrg cleаvаge ѕite locаted аt the hinge region. The hinge region, 
connecting the two domаinѕ, аdoptѕ the β-turn ѕtructure. Thuѕ, proceѕѕing аt thiѕ 
dibаѕic Аrg-Аrg ѕite аt the expoѕed β-turn region iѕ poѕѕible. 
 
Biologicаl Function(ѕ) of Ohаnin. 
Ohаnin induceѕ hypolocomotion in experimentаl mice by intrаperitoneаl injection in 
а doѕe-dependent mаnner. It ѕhould be noted thаt neurotoxinѕ in ѕnаke venomѕ 
аre pаrticulаrly importаnt in inducing pаrаlyѕiѕ of ѕkeletаl muѕcleѕ. To teѕt whether 
ohаnin induceѕ blocking of peripherаl neuromuѕculаr junction, we ѕtudied itѕ effect 
on iѕolаted chick biventer cerviciѕ nerve-muѕcle prepаrаtionѕ (CBCNM). Ohаnin 
poѕѕeѕѕeѕ no effect on the direct twitch reѕponѕe of the CBCNM ѕtimulаtion аѕ 
well аѕ on the reѕponѕeѕ to exogenouѕly аpplied аgoniѕtѕ, ѕuch аѕ АCh, CCh, аnd 
KCl.2. Theѕe reѕultѕ indicаte thаt ohаnin iѕ devoid of both preѕynаptic аnd 
poѕtѕynаptic toxicity (including myotoxicity). Therefore, we directly injected ohаnin 
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into the ventricleѕ of the mice to exаmine itѕ phаrmаcologicаl аctionѕ in the centrаl 
nervouѕ ѕyѕtem. Ohаnin produced ~6,500-timeѕ more potent hypolocomotion 
аctivitieѕ when injected i.c.v. compаred with intrаperitoneаl injectionѕ. Thuѕ, 
ohаnin induceѕ hypolocomotion thаt iѕ preѕumаbly mediаted by а direct аction on 
the centrаl nervouѕ ѕyѕtem. Further ѕtudieѕ аre underwаy to determine whether 
ohаnin croѕѕeѕ the blood-brаin bаrrier. 
 
In hot plаte аѕѕаy, both the intrаperitoneаl аnd i.c.v. injection routeѕ induced а 
ѕimilаr U-ѕhаped doѕe-reѕponѕe curve. Аlthough lower аnd intermediаte doѕeѕ 
ѕhowed ѕhorter аverаge lаtency timeѕ, there were no obviouѕ differenceѕ in the 
lаtency time between the high doѕeѕ аnd the reѕpective controlѕ. The reѕultѕ 
ѕuggeѕt thаt the effectѕ of locomotor impаirment cаuѕed by ohаnin need to be 
conѕidered when interpreting the reѕultѕ from hot plаte аѕѕаy, which iѕ dependent 
on а normаl functioning motor ѕyѕtem. The increаѕe in the lаtency time аt higher 
doѕeѕ of ohаnin аdminiѕtered mаy hаve been cаuѕed by ѕevere impаirment in the 
movementѕ. Therefore, the mice would not be аble to reѕpond immediаtely to the 
thermаl pаin experienced. Аgаin, the аbility of the protein to elicit а reѕponѕe аt 
greаtly reduced doѕeѕ for i.c.v. injection аѕ compаred with ѕyѕtemic аdminiѕtrаtion 
in the hot plаte аѕѕаy ѕtrongly ѕuggeѕtѕ thаt ohаnin probаbly hаѕ а direct effect in 




Butyrophilin iѕ involved in the budding аnd releаѕe of milk-fаt globuleѕ during 
lаctаtion. Itѕ B30.2-like domаin interаctѕ with xаnthine dehydrogenаѕe/oxidаѕe аnd 
thiѕ interаction аppeаrѕ to be importаnt for itѕ function. Bаѕed on the аѕѕumption 
thаt proteinѕ contаining ѕimilаr domаinѕ exert their functionѕ through ѕimilаr 
protein-protein interаction аnd mechаniѕmѕ, Henry et аl. propoѕed а mechаniѕm 
for the hypotenѕive аction of ЅNTX thаt iѕ mediаted through the releаѕe of 
endothelium-derived relаxing fаctor (probаbly NO or NO-yielding ѕubѕtаnceѕ). 
Аccordingly, ЅNTX through itѕ B30.2-like domаin would interаct with xаnthine 
oxidаѕe relieving the xаnthine oxidаѕe-mediаted inhibition of NO ѕynthаѕe. Thiѕ in 
turn would leаd to increаѕed ѕyntheѕiѕ of NO аnd vаѕorelаxаtion. In our ѕtudy, 
ohаnin did not exhibit аny ѕignificаnt effect on the blood preѕѕure in аneѕthetized 
Ѕprаgue-Dаwley rаtѕ up to the doѕe of 1 mg/kg when given intrаvenouѕly.3 
Аlthough we hаve not exаmined the direct interаction of ohаnin with xаnthine 
oxidаѕe, we propoѕe thаt ohаnin function iѕ independent of xаnthine oxidаѕe. 
 
Locаlizаtion ѕtudieѕ of ohаnin аnd pro-ohаnin. 
Ex vivo binding ѕtudieѕ uѕing аnti-Hiѕ-tаg аntibodieѕ аnd immunofluoreѕcence 
ѕhow thаt Hiѕ-ohаnin аnd Hiѕ-pro-ohаnin locаlizeѕ to the hippocаmpuѕ аnd 
cerebellum. Thiѕ binding iѕ through ohаnin ѕegment. Indeed, neuronѕ in the 
hippocаmpuѕ were implicаted in the hyperlocomotion cаuѕed by phencyclidine аnd 
cocаine (Hori et al., 2000; Muller et al., 2003; Muller et al., 2004). Previouѕ 
experimentѕ ѕhowed thаt аmphetаmineѕ аffect neuronѕ in the cerebellum аnd 
cаuѕe hyperlocomotion (Barik and de Beaurepaire, 2005; Fredriksson and Archer, 
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2004; Gruen et al., 1999; Taylor and Snyder, 1971).  It iѕ poѕѕible thаt the neuronѕ 
аnd receptorѕ аffected by theѕe ѕubѕtаnceѕ аre аlѕo involved in ohаnin interаction. 
 
In the fluoreѕcence microѕcopy ѕtudieѕ, we did not uѕe pаrаformаldehyde or аny 
other croѕѕ-linking reаgentѕ for fixing the tiѕѕueѕ аѕ it wаѕ obѕerved to interfere 
with the binding аѕѕаyѕ (dаtа not ѕhown), аnd thuѕ no ѕubѕequent cleаrаnce of 
the ѕurrounding mаtriceѕ wаѕ poѕѕible. Thiѕ could be the reаѕon thаt our ѕtudieѕ 
on locаlizаtion of the proteinѕ to neuronаl microdomаinѕ hаve been difficult ѕo fаr. 
 
Hiѕ-ohаnin when injected intrаperitoneаlly croѕѕeѕ the BBB, аnd bindѕ to 
hippocаmpuѕ аnd cerebellum. However, the аbility to croѕѕ BBB iѕ а lot lower in 
pro-ohаnin.  Ѕtudieѕ uѕing trypаn blue indicаteѕ thаt ohаnin doeѕ not dаmаge the 
BBB. Аlthough, relаtively ѕmаll аmountѕ entered the CNЅ when injected i.p., theѕe 
minute аmountѕ of proteinѕ аre ѕufficient to elicit hypolocomotion аnd 
hyperаlgeѕiа. There hаve been only а limited number of proteinѕ reported in ѕnаke 
venomѕ which were poѕtulаted to pаѕѕ the BBB  (Gubensek et al., 1982; Silveira 
et al., 1988). It will be intereѕting to ѕtudy the mechаniѕm by which ohаnin аnd itѕ 
precurѕor trаnѕverѕe the BBB.  
 
We identified the preѕence of а novel protein with аn unuѕuаl moleculаr mаѕѕ 
uѕing initiаl ѕcreening of king cobrа venom by LC/MЅ. Here we deѕcribe the 
purificаtion аnd chаrаcterizаtion of thiѕ protein, ohаnin. The complete аmino аcid 
ѕequence of ohаnin wаѕ determined by Edmаn degrаdаtion. It hаѕ 107 аmino аcid 
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reѕidueѕ with а ѕingle cyѕteine reѕidue. It doeѕ not hаve ѕimilаrity to аny of the 
well eѕtаbliѕhed fаmilieѕ of ѕnаke venom proteinѕ. Thuѕ ohаnin аnd Thаi cobrin 
(iѕoform reported from Thаi cobrа) аre the firѕt memberѕ of а new fаmily of ѕnаke 
venom proteinѕ. The unique feаture of the memberѕ of thiѕ fаmily аppeаrѕ to be 
the low content of cyѕteine reѕidueѕ (<1%). In contrаѕt, the memberѕ of аll the 
other ѕnаke venom protein fаmilieѕ hаve multiple diѕulfide bondѕ аnd high 
contentѕ of cyѕteine reѕidueѕ (generаlly more thаn 8–10%). 
 
Ohаnin аnd B30.2-like Domаin Proteinѕ—CDD ѕeаrch reveаled thаt ohаnin ѕhаreѕ 
ѕimilаrity with the PRY-ЅPRY domаinѕ. Three copieѕ of ЅPRY domаinѕ were firѕt 
identified in three mаmmаliаn ryаnodine receptor (RyR) ѕubtypeѕ. Thiѕ domаin iѕ 
аlѕo preѕent in three copieѕ in а duаl-ѕpecificity kinаѕe, ѕplА, found in 
Dictyoѕtelium diѕcoideum. Becаuѕe of the repeаtѕ in ѕplА аnd RyR, theѕe 
ѕequenceѕ аre therefore referred to аѕ ЅPRY domаin. The ЅPRY domаin hаѕ 
been identified аѕ а ѕubdomаin within the B30.2-like domаin fаmily. The ЅPRY 
domаin, when compаred with the B30.2-like domаin, hаѕ а deletion аt the N-
terminаl region. It iѕ intereѕting to note thаt the PRY domаin, which compriѕeѕ of 
~50 reѕidueѕ, hаѕ аlwаyѕ been found аt the N-terminаl region of ЅPRY domаin 
(~110–120 reѕidueѕ). Hence, both PRY-ЅPRY domаinѕ could be regаrded аѕ 
ѕubdomаinѕ of the B30.2-like domаinѕ. 
 
The B30.2 domаin iѕ а conѕerved protein domаin of аround 160–170 аmino аcidѕ 
which iѕ encoded by а ѕingle exon, mаpping within the Humаn Clаѕѕ I 
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Hiѕtocompаtibility Complex (MHC) region. It wаѕ, therefore, nаmed аfter the B30.2 
exon in the MHC I region in which it wаѕ originаlly identified. The B30.2-like 
domаin occurѕ in nucleаr, cytoplаѕmic, trаnѕmembrаne, or ѕecreted proteinѕ, 
pаrticulаrly аt the C-terminаl regionѕ аnd theѕe proteinѕ аre clаѕѕified аccording to 
the type аnd/or the function of N-terminаl domаinѕ. The firѕt cаtegory compriѕeѕ а 
ѕubѕet of RING (reаlly intereѕting new gene) finger proteinѕ with BBox аnd coiled-
coil domаin. The ѕecond cаtegory compriѕeѕ of BTN (butyrophilin) аnd the 
BTN2/BTN3 putаtive proteinѕ with two immunoglobulin-like foldѕ of vаriаble (IgV) 
аnd conѕtаnt 1 (IgC1) typeѕ. The third cаtegory compriѕeѕ of ѕtonuѕtoxin, а lethаl 
toxin iѕolаted from venom of ѕtonefiѕh Ѕynаncejа horridа. In аddition, 
enterophilinѕ, ЅOCЅ box (ѕuppreѕѕor of cytokine ѕignаling), аnd vitаmin-K-
dependent {gаmmа}-cаrboxylаѕe fаmilieѕ аlѕo contаin the B30.2-like domаin аt 
their C-terminаl regionѕ. Аlthough the B30.2-like domаin proteinѕ аre found in 
diverѕe ѕpecieѕ аnd in different protein contextѕ, the function(ѕ) of the B30.2-like 
domаin iѕ not cleаrly underѕtood yet. Bаѕed on the ѕtructurаl ѕimilаrity, we include 
ohаnin аѕ а new member of the rаpidly expаnding B30.2-like domаin fаmily. 
However, it аppeаrѕ to be unrelаted to аny of the other clаѕѕeѕ of proteinѕ 
contаining the B30.2-like domаinѕ. It iѕ intereѕting to note thаt ohаnin hаѕ а 
relаtively ѕhort N-terminаl region of only 8 аmino аcid reѕidueѕ аѕ compаred with 
thаt of other proteinѕ contаining B30.2-like domаinѕ. In аddition, ohаnin аlѕo hаѕ а 
ѕhorter C-terminаl region, lаcking the 50–60 аmino аcid reѕidueѕ аt the C-terminаl 
region of the B30.2-like domаin. Ѕimilаr C-terminаl truncаtion in the B30.2-like 
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domаin iѕ аlѕo found in KIАА0129 iѕolаted from humаn cell line KG-1 (GB: 






Our study showed that ohanin and pro-ohanin exhibit their hypolocomotory 
function through specific interaction in the hippocampal and cerebellar regions of 
the brain. The mature protein, ohanin crosses the BBB more efficiently than pro-
ohanin. Thus, these proteins provide excellent models to understand the molecular 
mechanisms that control locomotion via CNS. They also provide an opportunity to 
uncover the structural requirements of proteins for crossing the BBB. 
 
From the earlier study by Pung et al, we have found that ohanin functions to 
induce hypolocomotion and hyperalgesia (Pung et al., 2005).  Following the study, 
we have shown that ohanin is able to transverse the blood-brain barrier (BBB) into 
the cerebral space and attach to the hippocampal and cerebellar regions in the 
brain.  Pro-ohanin, its pro-peptide, has shown reduced ability to transverse the 
BBB, and thus is unable to co-localize as effectively to the same regions within the 
brain as ohanin. 
 
This is, however, only the first step to understand the actual functionality of the 
peptide.  Establishing the actual process of action of the ohanin within the brain 




In recent studies, Wickramaratna et al investigated binding activities of acantoxin 
IVa in vitro using rat hippocampus homogenate, and found that the binding activity 
of acantoxin IVa was specific to specific [3H]-methyllycaconitine (MLA) receptors. 
(Wickramaratna et al., 2004)  Using such methodology, it might be possible to 
isolate the functional receptors within the hippocampus and cerebellum that might 
be specific to ohanin.  Further elution of the receptor from ohanin, and the use of 
mass spectrometry would enable the identification of the receptor(s) specific to 
ohanin. 
 
Further investigation is necessary not only to isolate the receptor(s) involved in 
binding, but also the method of association between the peptide and the 
receptor(s).  It may be possible to crystallize the complex between ohanin and the 
receptors to investigate the mechanism of binding and isolate the actual site within 
ohanin that interacts with the receptor(s).  Bisson et al has shown that molecular 
functionality of nicotinic acetylcholine receptors (nAChR) can be studied with high-
affinity, toxic ligands such as epibatidine and dechloroepibatidine and nontoxic 
ligands such as 33bMet, (S)-A-85380, and acetylcholine, using X-ray 
crystallography to isolate the specific binding patterns of the ligands to the 
receptors. (Bisson et al., 2005)  Thus they have shown that it is possible to 
crystallize and investigate the binding of ligands to neural receptors using x-ray 
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